Cargando…
Prostate MRI and PSMA-PET in the Primary Diagnosis of Prostate Cancer
Over the last years, prostate magnetic resonance imaging (MRI) has gained a key role in the primary diagnosis of clinically significant prostate cancer (csPCa). While a negative MRI can avoid unnecessary prostate biopsies and the overdiagnosis of indolent cancers, a positive examination triggers bio...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10453091/ https://www.ncbi.nlm.nih.gov/pubmed/37627956 http://dx.doi.org/10.3390/diagnostics13162697 |
_version_ | 1785095837126230016 |
---|---|
author | Cereser, Lorenzo Evangelista, Laura Giannarini, Gianluca Girometti, Rossano |
author_facet | Cereser, Lorenzo Evangelista, Laura Giannarini, Gianluca Girometti, Rossano |
author_sort | Cereser, Lorenzo |
collection | PubMed |
description | Over the last years, prostate magnetic resonance imaging (MRI) has gained a key role in the primary diagnosis of clinically significant prostate cancer (csPCa). While a negative MRI can avoid unnecessary prostate biopsies and the overdiagnosis of indolent cancers, a positive examination triggers biopsy samples targeted to suspicious imaging findings, thus increasing the diagnosis of csPCa with a sensitivity and negative predictive value of around 90%. The limitations of MRI, including suboptimal positive predictive values, are fueling debate on how to stratify biopsy decisions and management based on patient risk and how to correctly estimate it with clinical and/or imaging findings. In this setting, “next-generation imaging” imaging based on radiolabeled Prostate-Specific Membrane Antigen (PSMA)-Positron Emission Tomography (PET) is expanding its indications both in the setting of primary staging (intermediate-to-high risk patients) and primary diagnosis (e.g., increasing the sensitivity of MRI or acting as a problem-solving tool for indeterminate MRI cases). This review summarizes the current main evidence on the role of prostate MRI and PSMA-PET as tools for the primary diagnosis of csPCa, and the different possible interaction pathways in this setting. |
format | Online Article Text |
id | pubmed-10453091 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-104530912023-08-26 Prostate MRI and PSMA-PET in the Primary Diagnosis of Prostate Cancer Cereser, Lorenzo Evangelista, Laura Giannarini, Gianluca Girometti, Rossano Diagnostics (Basel) Review Over the last years, prostate magnetic resonance imaging (MRI) has gained a key role in the primary diagnosis of clinically significant prostate cancer (csPCa). While a negative MRI can avoid unnecessary prostate biopsies and the overdiagnosis of indolent cancers, a positive examination triggers biopsy samples targeted to suspicious imaging findings, thus increasing the diagnosis of csPCa with a sensitivity and negative predictive value of around 90%. The limitations of MRI, including suboptimal positive predictive values, are fueling debate on how to stratify biopsy decisions and management based on patient risk and how to correctly estimate it with clinical and/or imaging findings. In this setting, “next-generation imaging” imaging based on radiolabeled Prostate-Specific Membrane Antigen (PSMA)-Positron Emission Tomography (PET) is expanding its indications both in the setting of primary staging (intermediate-to-high risk patients) and primary diagnosis (e.g., increasing the sensitivity of MRI or acting as a problem-solving tool for indeterminate MRI cases). This review summarizes the current main evidence on the role of prostate MRI and PSMA-PET as tools for the primary diagnosis of csPCa, and the different possible interaction pathways in this setting. MDPI 2023-08-17 /pmc/articles/PMC10453091/ /pubmed/37627956 http://dx.doi.org/10.3390/diagnostics13162697 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Cereser, Lorenzo Evangelista, Laura Giannarini, Gianluca Girometti, Rossano Prostate MRI and PSMA-PET in the Primary Diagnosis of Prostate Cancer |
title | Prostate MRI and PSMA-PET in the Primary Diagnosis of Prostate Cancer |
title_full | Prostate MRI and PSMA-PET in the Primary Diagnosis of Prostate Cancer |
title_fullStr | Prostate MRI and PSMA-PET in the Primary Diagnosis of Prostate Cancer |
title_full_unstemmed | Prostate MRI and PSMA-PET in the Primary Diagnosis of Prostate Cancer |
title_short | Prostate MRI and PSMA-PET in the Primary Diagnosis of Prostate Cancer |
title_sort | prostate mri and psma-pet in the primary diagnosis of prostate cancer |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10453091/ https://www.ncbi.nlm.nih.gov/pubmed/37627956 http://dx.doi.org/10.3390/diagnostics13162697 |
work_keys_str_mv | AT cereserlorenzo prostatemriandpsmapetintheprimarydiagnosisofprostatecancer AT evangelistalaura prostatemriandpsmapetintheprimarydiagnosisofprostatecancer AT giannarinigianluca prostatemriandpsmapetintheprimarydiagnosisofprostatecancer AT giromettirossano prostatemriandpsmapetintheprimarydiagnosisofprostatecancer |